WheltonPK, CareyRM, AronowWS, CaseyJrDE, CollinsKJ, Dennison HimmelfarbC, et al.: 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension71: e13–e115, 2018
WheltonPK, CareyRM, AronowWS, CaseyJrDE, CollinsKJ, Dennison HimmelfarbC, : 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension 71: e13–e115, 2018)| false
CareyRM, CalhounDA, BakrisGL, BrookRD, DaughertySL, Dennison-HimmelfarbCR, et al.; American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council: Resistant hypertension: Detection, evaluation, and management: A scientific statement from the American Heart Association. Hypertension72: e53–e90, 2018PubMed
CareyRM, CalhounDA, BakrisGL, BrookRD, DaughertySL, Dennison-HimmelfarbCR, ; American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council: Resistant hypertension: Detection, evaluation, and management: A scientific statement from the American Heart Association. Hypertension 72: e53–e90, 2018PubMed10.1161/HYP.0000000000000084)| false
BrownJM, Robinson-CohenC, Luque-FernandezMA, AllisonMA, BaudrandR, IxJH, et al.: The spectrum of subclinical primary aldosteronism and incident hypertension: A cohort study. Ann Intern Med167: 630–641, 2017PubMed
BrownJM, Robinson-CohenC, Luque-FernandezMA, AllisonMA, BaudrandR, IxJH, : The spectrum of subclinical primary aldosteronism and incident hypertension: A cohort study. Ann Intern Med 167: 630–641, 2017PubMed10.7326/M17-0882)| false
BrownJM, SiddiquiM, CalhounDA, CareyRM, HopkinsPN, WilliamsGH, et al.: The unrecognized prevalence of primary aldosteronism: A cross-sectional study. Ann Intern Med173: 10–20, 2020PubMed
BrownJM, SiddiquiM, CalhounDA, CareyRM, HopkinsPN, WilliamsGH, : The unrecognized prevalence of primary aldosteronism: A cross-sectional study. Ann Intern Med 173: 10–20, 2020PubMed10.7326/M20-0065)| false
JosephJJ, PohlmanNK, ZhaoS, KlineD, BrockG, Echouffo-TcheuguiJB, et al.: Association of serum aldosterone and plasma renin activity with ambulatory blood pressure in African Americans: The Jackson heart study. Circulation143: 2355–2366, 2021PubMed
JosephJJ, PohlmanNK, ZhaoS, KlineD, BrockG, Echouffo-TcheuguiJB, : Association of serum aldosterone and plasma renin activity with ambulatory blood pressure in African Americans: The Jackson heart study. Circulation 143: 2355–2366, 2021PubMed10.1161/CIRCULATIONAHA.120.050896)| false
CareyRM, SakhujaS, CalhounDA, WheltonPK, MuntnerP: Prevalence of apparent treatment-resistant hypertension in the United States. Hypertension73: 424–431, 2019PubMed
CareyRM, SakhujaS, CalhounDA, WheltonPK, MuntnerP: Prevalence of apparent treatment-resistant hypertension in the United States. Hypertension 73: 424–431, 2019PubMed10.1161/HYPERTENSIONAHA.118.12191)| false
TannerRM, CalhounDA, BellEK, BowlingCB, GutiérrezOM, IrvinMR, et al.: Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol8: 1583–1590, 2013PubMed
ThomasG, XieD, ChenHY, AndersonAH, AppelLJ, BodanaS, et al.; CRIC Study Investigators: Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: Report from the chronic renal insufficiency cohort study. Hypertension67: 387–396, 2016PubMed
RuzickaM, LeenenFHH, RamsayT, BugejaA, EdwardsC, McCormickB, et al.: Use of directly observed therapy to assess treatment adherence in patients with apparent treatment-resistant hypertension. JAMA Intern Med179: 1433–1434, 2019PubMed
RuzickaM, LeenenFHH, RamsayT, BugejaA, EdwardsC, McCormickB, : Use of directly observed therapy to assess treatment adherence in patients with apparent treatment-resistant hypertension. JAMA Intern Med 179: 1433–1434, 2019PubMed10.1001/jamainternmed.2019.1455)| false
EganBM, ZhaoY, LiJ, BrzezinskiWA, TodoranTM, BrookRD, et al.: Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension62: 691–697, 2013PubMed
EganBM, ZhaoY, LiJ, BrzezinskiWA, TodoranTM, BrookRD, : Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension 62: 691–697, 2013PubMed10.1161/HYPERTENSIONAHA.113.01448)| false
EganBM, ZhaoY, AxonRN, BrzezinskiWA, FerdinandKC: Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation124: 1046–1058, 2011PubMed
EganBM, ZhaoY, AxonRN, BrzezinskiWA, FerdinandKC: Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 124: 1046–1058, 2011PubMed10.1161/CIRCULATIONAHA.111.030189)| false
McMahonEJ, BauerJD, HawleyCM, IsbelNM, StowasserM, JohnsonDW, et al.: A randomized trial of dietary sodium restriction in CKD. J Am Soc Nephrol24: 2096–2103, 2013PubMed
RoereckeM, KaczorowskiJ, TobeSW, GmelG, HasanOSM, RehmJ: The effect of a reduction in alcohol consumption on blood pressure: A systematic review and meta-analysis. Lancet Public Health2: e108–e120, 2017PubMed
RoereckeM, KaczorowskiJ, TobeSW, GmelG, HasanOSM, RehmJ: The effect of a reduction in alcohol consumption on blood pressure: A systematic review and meta-analysis. Lancet Public Health 2: e108–e120, 2017PubMed10.1016/S2468-2667(17)30003-8)| false
LopesS, Mesquita-BastosJ, GarciaC, BertoquiniS, RibauV, TeixeiraM, et al.: Effect of exercise training on ambulatory blood pressure among patients with resistant hypertension: A randomized clinical trial. JAMA Cardiol6: 1317–1323, 2021PubMed
LopesS, Mesquita-BastosJ, GarciaC, BertoquiniS, RibauV, TeixeiraM, : Effect of exercise training on ambulatory blood pressure among patients with resistant hypertension: A randomized clinical trial. JAMA Cardiol 6: 1317–1323, 2021PubMed10.1001/jamacardio.2021.2735)| false
De la SierraA, BanegasJR, OliverasA, GorostidiM, SeguraJ, de la CruzJJ, et al.: Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs. J Hypertens30: 1211–1216, 2012PubMed
De la SierraA, BanegasJR, OliverasA, GorostidiM, SeguraJ, de la CruzJJ, : Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs. J Hypertens 30: 1211–1216, 2012PubMed10.1097/HJH.0b013e328353634e)| false
De la SierraA, SeguraJ, BanegasJR, GorostidiM, de la CruzJJ, ArmarioP, et al.: Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension57: 898–902, 2011PubMed
De la SierraA, SeguraJ, BanegasJR, GorostidiM, de la CruzJJ, ArmarioP, : Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 57: 898–902, 2011PubMed10.1161/HYPERTENSIONAHA.110.168948)| false
CohenJB, LotitoMJ, TrivediUK, DenkerMG, CohenDL, TownsendRR: Cardiovascular events and mortality in white coat hypertension: A systematic review and meta-analysis. Ann Intern Med170: 853–862, 2019PubMed
CohenJB, LotitoMJ, TrivediUK, DenkerMG, CohenDL, TownsendRR: Cardiovascular events and mortality in white coat hypertension: A systematic review and meta-analysis. Ann Intern Med 170: 853–862, 2019PubMed10.7326/M19-0223)| false
HundemerGL, KlineGA, LeungAA: How common is primary aldosteronism?Curr Opin Nephrol Hypertens 30: 353–360, 2021PubMed10.1097/MNH.0000000000000702)| false
FunderJW, CareyRM, ManteroF, MuradMH, ReinckeM, ShibataH, et al.: The management of primary aldosteronism: Case detection, diagnosis, and treatment: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab101: 1889–1916, 2016PubMed
FunderJW, CareyRM, ManteroF, MuradMH, ReinckeM, ShibataH, : The management of primary aldosteronism: Case detection, diagnosis, and treatment: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 101: 1889–1916, 2016PubMed10.1210/jc.2015-4061)| false
VasanRS, EvansJC, LarsonMG, WilsonPW, MeigsJB, RifaiN, et al.: Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med351: 33–41, 2004PubMed
VasanRS, EvansJC, LarsonMG, WilsonPW, MeigsJB, RifaiN, : Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 351: 33–41, 2004PubMed10.1056/NEJMoa033263)| false
Newton-ChehC, GuoCY, GonaP, LarsonMG, BenjaminEJ, WangTJ, et al.: Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension49: 846–856, 2007PubMed
Newton-ChehC, GuoCY, GonaP, LarsonMG, BenjaminEJ, WangTJ, : Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 49: 846–856, 2007PubMed10.1161/01.HYP.0000258554.87444.91)| false
KimSK, McCurleyAT, DuPontJJ, AronovitzM, MossME, StillmanIE, et al.: Smooth muscle cell-mineralocorticoid receptor as a mediator of cardiovascular stiffness with aging. Hypertension71: 609–621, 2018PubMed
MonticoneS, D’AscenzoF, MorettiC, WilliamsTA, VeglioF, GaitaF, et al.: Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: A systematic review and meta-analysis. Lancet Diabetes Endocrinol6: 41–50, 2018PubMed
CohenJB, CohenDL, HermanDS, LeppertJT, ByrdJB, BhallaV: Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. veterans: A retrospective cohort study. Ann Intern Med174: 289–297, 2021PubMed
CohenJB, CohenDL, HermanDS, LeppertJT, ByrdJB, BhallaV: Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. veterans: A retrospective cohort study. Ann Intern Med 174: 289–297, 2021PubMed10.7326/M20-4873)| false
HundemerGL, ImsirovicH, VaidyaA, Yozamp N, Goupil R, Madore F, et al.: Screening rates for primary aldosteronism among individuals with hypertension plus hypokalemia: A population-based retrospective cohort study. Hypertension79: 178–186, 2021PubMed
HundemerGL, VaidyaA: Primary aldosteronism diagnosis and management: A clinical approach. Endocrinol Metab Clin North Am 48: 681–700, 2019PubMed10.1016/j.ecl.2019.08.002)| false
HungA, AhmedS, GuptaA, Davis A, Kline GA, Leung AA, et al.: Performance of the aldosterone-to-renin ratio as a screening test for primary aldosteronism: A systematic review and meta-analysis. J Clin Endocrinol Metab106: 2423–2435, 2021
HungA, AhmedS, GuptaA, Davis A, Kline GA, Leung AA, : Performance of the aldosterone-to-renin ratio as a screening test for primary aldosteronism: A systematic review and meta-analysis. J Clin Endocrinol Metab 106: 2423–2435, 202110.1210/clinem/dgab348)| false
KempersMJ, LendersJW, van OutheusdenL, van der WiltGJ, Schultze KoolLJ, HermusAR, et al.: Systematic review: Diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med151: 329–337, 2009PubMed
KempersMJ, LendersJW, van OutheusdenL, van der WiltGJ, Schultze KoolLJ, HermusAR, : Systematic review: Diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med 151: 329–337, 2009PubMed10.7326/0003-4819-151-5-200909010-00007)| false
WilliamsTA, LendersJWM, MulateroP, BurrelloJ, RottenkolberM, AdolfC, et al.; Primary Aldosteronism Surgery Outcome (PASO) investigators: Outcomes after adrenalectomy for unilateral primary aldosteronism: An international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol5: 689–699, 2017PubMed
WilliamsTA, LendersJWM, MulateroP, BurrelloJ, RottenkolberM, AdolfC, ; Primary Aldosteronism Surgery Outcome (PASO) investigators: Outcomes after adrenalectomy for unilateral primary aldosteronism: An international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 5: 689–699, 2017PubMed10.1016/S2213-8587(17)30135-3)| false
KöhlerA, SarkisAL, HeinrichDA, MüllerL, HandgriffL, DenizS, et al.: Renin, a marker for left ventricular hypertrophy, in primary aldosteronism: A cohort study. Eur J Endocrinol185: 663–672, 2021PubMed
De BruyneB, ManoharanG, PijlsNH, VerhammeK, MadaricJ, BartunekJ, et al.: Assessment of renal artery stenosis severity by pressure gradient measurements. J Am Coll Cardiol48: 1851–1855, 2006PubMed
OlinJW, FroehlichJ, GuX, BacharachJM, EagleK, GrayBH, et al.: The United States Registry for Fibromuscular Dysplasia: Results in the first 447 patients. Circulation125: 3182–3190, 2012PubMed
OlinJW, FroehlichJ, GuX, BacharachJM, EagleK, GrayBH, : The United States Registry for Fibromuscular Dysplasia: Results in the first 447 patients. Circulation 125: 3182–3190, 2012PubMed10.1161/CIRCULATIONAHA.112.091223)| false
CooperCJ, MurphyTP, CutlipDE, JamersonK, HenrichW, ReidDM, et al.; CORAL Investigators: Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med370: 13–22, 2014PubMed
CooperCJ, MurphyTP, CutlipDE, JamersonK, HenrichW, ReidDM, ; CORAL Investigators: Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 370: 13–22, 2014PubMed10.1056/NEJMoa1310753)| false
WheatleyK, IvesN, GrayR, KalraPA, MossJG, BaigentC, et al.; ASTRAL Investigators: Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med361: 1953–1962, 2009PubMed
WheatleyK, IvesN, GrayR, KalraPA, MossJG, BaigentC, ; ASTRAL Investigators: Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 361: 1953–1962, 2009PubMed10.1056/NEJMoa0905368)| false
BaxL, WoittiezAJ, KouwenbergHJ, MaliWPTM.BuskensE.BeekFJA et al.: Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: A randomized trial. Ann Intern Med150: 840–848, 2009PubMed
BaxL, WoittiezAJ, KouwenbergHJ, MaliWPTM.BuskensE.BeekFJA: Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: A randomized trial. Ann Intern Med 150: 840–848, 2009PubMed10.7326/0003-4819-150-12-200906160-00119)| false
TrinquartL, Mounier-VehierC, SapovalM, GagnonN, PlouinPF: Efficacy of revascularization for renal artery stenosis caused by fibromuscular dysplasia: A systematic review and meta-analysis. Hypertension56: 525–532, 2010PubMed
LendersJW, DuhQY, EisenhoferG, Gimenez-RoqueploAP, GrebeSK, MuradMH, et al.; Endocrine Society: Pheochromocytoma and paraganglioma: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab99: 1915–1942, 2014PubMed
StolkRF, BakxC, MulderJ, TimmersHJ, LendersJW: Is the excess cardiovascular morbidity in pheochromocytoma related to blood pressure or to catecholamines?J Clin Endocrinol Metab98: 1100–1106, 2013PubMed
StolkRF, BakxC, MulderJ, TimmersHJ, LendersJW: Is the excess cardiovascular morbidity in pheochromocytoma related to blood pressure or to catecholamines?J Clin Endocrinol Metab 98: 1100–1106, 2013PubMed10.1210/jc.2012-3669)| false
MuntnerP, AndersonA, CharlestonJ, ChenZ, FordV, MakosG, et al.; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators: Hypertension awareness, treatment, and control in adults with CKD: Results from the chronic renal insufficiency cohort (CRIC) study. Am J Kidney Dis55: 441–451, 2010PubMed
MuntnerP, AndersonA, CharlestonJ, ChenZ, FordV, MakosG, ; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators: Hypertension awareness, treatment, and control in adults with CKD: Results from the chronic renal insufficiency cohort (CRIC) study. Am J Kidney Dis 55: 441–451, 2010PubMed10.1053/j.ajkd.2009.09.014)| false
De NicolaL, GabbaiFB, AgarwalR, ChiodiniP, BorrelliS, BellizziV, et al.: Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol61: 2461–2467, 2013PubMed
De NicolaL, GabbaiFB, AgarwalR, ChiodiniP, BorrelliS, BellizziV, : Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol 61: 2461–2467, 2013PubMed10.1016/j.jacc.2012.12.061)| false
MuntnerP, HeJ, HammL, LoriaC, WheltonPK: Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol13: 745–753, 2002PubMed
MuntnerP, HeJ, HammL, LoriaC, WheltonPK: Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 13: 745–753, 2002PubMed10.1681/ASN.V133745)| false
Pratt-UbunamaMN, NishizakaMK, BoedefeldRL, CofieldSS, HardingSM, CalhounDA: Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest131: 453–459, 2007PubMed
Pratt-UbunamaMN, NishizakaMK, BoedefeldRL, CofieldSS, HardingSM, CalhounDA: Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 131: 453–459, 2007PubMed10.1378/chest.06-1442)| false
YangL, ZhangH, CaiM, ZouY, JiangX, SongL, et al.: Effect of spironolactone on patients with resistant hypertension and obstructive sleep apnea. Clin Exp Hypertens38: 464–468, 2016PubMed
BrattonDJ, GaislT, WonsAM, KohlerM: CPAP vs mandibular advancement devices and blood pressure in patients with obstructive sleep apnea: A systematic review and meta-analysis. JAMA314: 2280–2293, 2015PubMed
BrattonDJ, GaislT, WonsAM, KohlerM: CPAP vs mandibular advancement devices and blood pressure in patients with obstructive sleep apnea: A systematic review and meta-analysis. JAMA 314: 2280–2293, 2015PubMed10.1001/jama.2015.16303)| false
McEvoyRD, AnticNA, HeeleyE, LuoY, OuQ, ZhangX, et al.; SAVE Investigators and Coordinators: CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med375: 919–931, 2016PubMed
McEvoyRD, AnticNA, HeeleyE, LuoY, OuQ, ZhangX, ; SAVE Investigators and Coordinators: CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med 375: 919–931, 2016PubMed10.1056/NEJMoa1606599)| false
StoutKK, DanielsCJ, AboulhosnJA, BozkurtB, BrobergCS, ColmanJM, et al.: 2018 AHA/ACC guideline for the management of adults with congenital heart disease: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol73: e81–e192, 2019PubMed
StoutKK, DanielsCJ, AboulhosnJA, BozkurtB, BrobergCS, ColmanJM, : 2018 AHA/ACC guideline for the management of adults with congenital heart disease: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol 73: e81–e192, 2019PubMed10.1016/j.jacc.2018.08.1029)| false
JohnsonAG, NguyenTV, DayRO: Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 121: 289–300, 1994PubMed10.7326/0003-4819-121-4-199408150-00011)| false
Chasan-TaberL, WillettWC, MansonJE, SpiegelmanD, HunterDJ, CurhanG, et al.: Prospective study of oral contraceptives and hypertension among women in the United States. Circulation94: 483–489, 1996PubMed
Chasan-TaberL, WillettWC, MansonJE, SpiegelmanD, HunterDJ, CurhanG, : Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 94: 483–489, 1996PubMed10.1161/01.CIR.94.3.483)| false
Abdel-QadirH, EthierJL, LeeDS, ThavendiranathanP, AmirE: Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. Cancer Treat Rev53: 120–127, 2017PubMed
Abdel-QadirH, EthierJL, LeeDS, ThavendiranathanP, AmirE: Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. Cancer Treat Rev 53: 120–127, 2017PubMed10.1016/j.ctrv.2016.12.002)| false
MirO, RopertS, AlexandreJ, GoldwasserF: Hypertension as a surrogate marker for the activity of anti-VEGF agents. Ann Oncol 20: 967–970, 2009PubMed10.1093/annonc/mdp206)| false
ValassiE, SantosA, YanevaM, TóthM, StrasburgerCJ, ChansonP, et al.; ERCUSYN Study Group: The European Registry on Cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol165: 383–392, 2011PubMed
NiemanLK: Hypertension and cardiovascular mortality in patients with Cushing syndrome. Endocrinol Metab Clin North Am 48: 717–725, 2019PubMed10.1016/j.ecl.2019.08.005)| false
WilliamsB, MacDonaldTM, MorantS, WebbDJ, SeverP, McInnesG, et al.; British Hypertension Society’s PATHWAY Studies Group: Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial. Lancet386: 2059–2068, 2015PubMed
WilliamsB, MacDonaldTM, MorantSV, WebbDJ, SeverP, McInnesGT, et al.; British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group: Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: The PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol6: 464–475, 2018PubMed
WilliamsB, MacDonaldTM, MorantSV, WebbDJ, SeverP, McInnesGT, ; British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group: Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: The PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol 6: 464–475, 2018PubMed10.1016/S2213-8587(18)30071-8)| false